GLP-1 Receptor Expression in CHI (NCT03768518) | Clinical Trial Compass
UnknownNot Applicable
GLP-1 Receptor Expression in CHI
Netherlands40 participantsStarted 2018-02-07
Plain-language summary
The primary objective is the in vivo and ex vivo investigation of the expression and distribution of the GLP-1R in the pancreas of CHI patients.
Who can participate
Age range16 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Biochemically and clinically proven endogenous congenital hyperinsulinism:
* Unresponsive to medical treatment (diazoxide)
* Indication for 18F-DOPA PET/CT based on mutation analysis
* Standard imaging (18F-DOPA PET/CT) not older than 8 weeks
* \<16 years old
* Informed consent signed by parents or legal guardians of the patient.
Exclusion Criteria:
* Genetically proven diffuse CHI (presenting with a homozygous or compound heterozygous ABCC8/KCNJ11 mutation)
* Calculated creatinine clearance below 40 ml/min
* Evidence of other malignancy than insulin producing tumors in conventional imaging (suspicious liver, bone and lung lesions based on CT)
* Age \> 16 years
* No signed informed consent
What they're measuring
1
Expression and distribution of GLP-1R in pancreas of children with CHI